HCM
PCRX icon

Hollencrest Capital Management’s Pacira BioSciences PCRX Stock Holding History

Hollencrest Capital Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-428
Closed -$10.6K – 1175
2025
Q1 		$10.6K Buy
+428
New +$10.2K ﹤0.01% 759

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Hollencrest Capital Management's PCRX Position: Q2 2025 in Review

Hollencrest Capital Management sold out of Pacira BioSciences (PCRX) in Q2 2025, closing a stake of 428 shares — an estimated $10.6K sold.

Hollencrest Capital Management first reported a position in PCRX in Q1 2025 and held it in 1 quarter. The position peaked at $10.6K in Q1 2025. 233 funds tracked by Wall St. Rank hold PCRX as of Q2 2025.

  • Hollencrest Capital Management reported no remaining Pacira BioSciences position as of Q2 2025 after selling out during the quarter.
  • Hollencrest Capital Management sold 428 Pacira BioSciences shares in Q2 2025, an estimated $10.6K.
  • Hollencrest Capital Management first reported a position in Pacira BioSciences in Q1 2025 and held it in 1 quarter.
  • Hollencrest Capital Management's Pacira BioSciences position peaked at $10.6K in Q1 2025.
  • 233 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2025.

Based on Hollencrest Capital Management's 13F filing for Q2 2025, filed 18 Aug 2025.